Bio-Techne Reports Q4 Earnings, Acquisition by Merck Moves Forward
Bio-Techne Corporation (NASDAQ: TECH) has reported its financial results for the fourth quarter ending June 30, 2026. The company's organic revenue increased by 3% to $321.2 million in the fourth quarter and remained flat at $1.2 billion for the full year. GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year, while adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year.
The company's Protein Sciences segment reported a 2% increase in net sales to $231.2 million, with organic revenue increasing by 1%. However, operating margin for the segment decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025.
Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany is moving forward, with the company expecting a total enterprise value of approximately $11.3 billion at a price of $73 per share in cash.